News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
815,525 Results
Type
Article (74216)
Company Profile (643)
Press Release (740666)
Multimedia
Podcasts (124)
Webinars (14)
Section
Business (226508)
Career Advice (3717)
Deals (39172)
Drug Delivery (129)
Drug Development (89015)
Employer Resources (198)
FDA (17814)
Job Trends (17089)
News (386162)
Policy (38648)
Tag
Academia (2999)
Academic (1)
Accelerated approval (6)
Adcomms (29)
Allergies (96)
Alliances (55847)
ALS (105)
Alzheimer's disease (1506)
Antibody-drug conjugate (ADC) (164)
Approvals (17769)
Artificial intelligence (307)
Autoimmune disease (29)
Automation (16)
Bankruptcy (402)
Best Places to Work (12632)
BIOSECURE Act (22)
Biosimilars (120)
Biotechnology (439)
Bladder cancer (85)
Brain cancer (32)
Breast cancer (313)
Cancer (2484)
Cardiovascular disease (210)
Career advice (3166)
Career pathing (34)
CAR-T (177)
Cell therapy (491)
Cervical cancer (22)
Clinical research (72007)
Collaboration (935)
Company closure (2)
Compensation (585)
Complete response letters (30)
COVID-19 (2868)
CRISPR (50)
C-suite (275)
Cystic fibrosis (109)
Data (2367)
Decentralized trials (2)
Denatured (41)
Depression (56)
Diabetes (302)
Diagnostics (6925)
Digital health (20)
Diversity (9)
Diversity, equity & inclusion (48)
Drug discovery (132)
Drug pricing (130)
Drug shortages (33)
Duchenne muscular dystrophy (104)
Earnings (93733)
Editorial (47)
Employer branding (25)
Employer resources (167)
Events (128908)
Executive appointments (788)
FDA (19243)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (826)
Gene editing (125)
Generative AI (27)
Gene therapy (364)
GLP-1 (860)
Government (5121)
Grass and pollen (6)
Guidances (151)
Healthcare (20874)
Huntington's disease (26)
IgA nephropathy (31)
Immunology and inflammation (152)
Indications (30)
Infectious disease (3032)
Inflammatory bowel disease (159)
Inflation Reduction Act (11)
Influenza (58)
Intellectual property (102)
Interviews (727)
IPO (17732)
IRA (51)
Job creations (4940)
Job search strategy (2589)
Kidney cancer (11)
Labor market (47)
Layoffs (564)
Leadership (24)
Legal (9887)
Liver cancer (82)
Lung cancer (349)
Lymphoma (162)
Machine learning (9)
Management (65)
Manufacturing (363)
MASH (83)
Medical device (14623)
Medtech (14628)
Mergers & acquisitions (22008)
Metabolic disorders (809)
Multiple sclerosis (89)
NASH (23)
Neurodegenerative disease (118)
Neuropsychiatric disorders (34)
Neuroscience (2123)
NextGen: Class of 2025 (7634)
Non-profit (5080)
Now hiring (41)
Obesity (433)
Opinion (276)
Ovarian cancer (83)
Pain (105)
Pancreatic cancer (91)
Parkinson's disease (162)
Partnered (22)
Patents (258)
Patient recruitment (119)
Peanut (51)
People (63847)
Pharmaceutical (132)
Pharmacy benefit managers (22)
Phase I (22250)
Phase II (31417)
Phase III (23693)
Pipeline (1401)
Policy (181)
Postmarket research (3239)
Preclinical (9808)
Press Release (72)
Prostate cancer (114)
Psychedelics (38)
Radiopharmaceuticals (270)
Rare diseases (436)
Real estate (7112)
Recruiting (75)
Regulatory (26009)
Reports (58)
Research institute (2655)
Resumes & cover letters (579)
Rett syndrome (5)
RNA editing (5)
RSV (50)
Schizophrenia (82)
Series A (144)
Series B (94)
Service/supplier (26)
Sickle cell disease (59)
Special edition (20)
Spinal muscular atrophy (165)
Sponsored (34)
Startups (4189)
State (2)
Stomach cancer (16)
Supply chain (75)
Tariffs (54)
The Weekly (81)
Vaccines (822)
Venture capitalists (45)
Weight loss (307)
Women's health (38)
Worklife (20)
Date
Today (30)
Last 7 days (988)
Last 30 days (3153)
Last 365 days (34891)
2025 (12574)
2024 (37887)
2023 (42567)
2022 (53926)
2021 (58722)
2020 (57663)
2019 (51302)
2018 (39083)
2017 (36786)
2016 (37675)
2015 (43661)
2014 (38254)
2013 (34183)
2012 (36131)
2011 (36206)
2010 (35533)
Location
Africa (1186)
Alabama (61)
Alaska (7)
Arizona (245)
Arkansas (14)
Asia (48561)
Australia (8335)
California (6688)
Canada (2108)
China (577)
Colorado (289)
Connecticut (305)
Delaware (166)
Europe (109709)
Florida (978)
Georgia (226)
Hawaii (1)
Idaho (63)
Illinois (623)
India (30)
Indiana (343)
Iowa (12)
Japan (177)
Kansas (112)
Kentucky (28)
Louisiana (15)
Maine (70)
Maryland (991)
Massachusetts (5109)
Michigan (249)
Minnesota (430)
Mississippi (2)
Missouri (92)
Montana (31)
Nebraska (26)
Nevada (69)
New Hampshire (69)
New Jersey (1880)
New Mexico (31)
New York (1878)
North Carolina (1142)
North Dakota (9)
Northern California (2884)
Ohio (224)
Oklahoma (15)
Oregon (46)
Pennsylvania (1464)
Puerto Rico (14)
Rhode Island (36)
South America (1561)
South Carolina (26)
South Dakota (1)
Southern California (2484)
Tennessee (108)
Texas (994)
United States (25455)
Utah (199)
Virginia (175)
Washington D.C. (72)
Washington State (612)
West Virginia (3)
Wisconsin (70)
815,525 Results for "kyowa hakko kogyo co ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
epitoMAP Inc., Animal Allergy Clinical Laboratories Inc. and Nippon Zenyaku Kogyo Co., Ltd. Enter into License Agreement
epitoMAP Inc. and Animal Allergy Clinical Laboratories Inc. entered into a License Agreement for an antibody pharmaceutical for veterinary use, CRE-DR-B, with Nippon Zenyaku Kogyo Co., Ltd. on November 10, 2023.
November 17, 2023
·
2 min read
Business
Kyowa Kirin Announces Board Approval for Construction of New Biologics Manufacturing Plant in Sanford, NC
Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd., a global specialty pharmaceutical company based in Japan, announced that its board of directors has approved plans to invest up to $530 million to build a new, state-of-the-art manufacturing facility in Sanford, North Carolina.
June 10, 2024
·
4 min read
Press Releases
Kura Oncology and Kyowa Kirin Announce Submission of New Drug Application for Ziftomenib to FDA
April 9, 2025
·
7 min read
Press Releases
AriBio Co., Ltd. and Fujirebio Diagnostics, Inc. Announce Completion of Sample Set for the Strategic Partnership Implemented to Advance Biomarker Development for Alzheimer’s Disease and Neurodegeneration
May 9, 2025
·
3 min read
Press Releases
WORK Medical Technology Group LTD Announces Strategic Partnership with Shanghai Chartwell Medical Device Co., Ltd.
March 3, 2025
·
5 min read
Press Releases
Kyowa Kirin Announces Late-Breaking Abstract Presentation at the American Academy of Dermatology Annual Meeting 2025
February 26, 2025
·
4 min read
Deals
Kyowa Kirin successfully completes acquisition of Orchard Therapeutics, a global gene therapy leader for rare diseases
Kyowa Kirin Co., Ltd. a Japan-based global specialty pharmaceutical company discovering and developing novel medicines utilizing the latest biotechnology, and Orchard Therapeutics plc, a global gene therapy leader, announced Kyowa Kirin has successfully completed the acquisition of Orchard Therapeutics.
January 24, 2024
·
9 min read
Pharm Country
Kyowa Kirin Will Present Pre-Clinical Data at the Association for Research in Vision and Ophthalmology Annual Meeting 2024
Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that data from the pre-clinical pharmacokinetics & efficacy study comparing ocular tissue distribution after ocular instillation of tivozanib eye drops will be presented at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting to be held in Seattle, Washington from May 5-9, 2024.
May 8, 2024
·
4 min read
Press Releases
Kura Oncology and Kyowa Kirin Announce Positive Ziftomenib Monotherapy Registrational Trial and Positive FDA Feedback for Upcoming Frontline Combination Trial Designs
February 5, 2025
·
14 min read
Press Releases
Merck Enters Exclusive License Agreement for HRS-5346, an Investigational Oral Lipoprotein(a) Inhibitor, for Cardiovascular Disease from Jiangsu Hengrui Pharmaceuticals Co., Ltd.
March 25, 2025
·
5 min read
1 of 81,553
Next
